Medacta sets sights on IPO
Medacta is planning to launch an IPO in the second half of 2019 on the SIX Swiss Exchange, as outlined in a press release. Founder Alberto Siccardi and his family intend to remain as majority shareholders even after the IPO.
Medacta develops and produces orthopedic implants and instruments to help with problems related to hips, knees, shoulders and the spine. In financial year 2018, the company recorded sales of 273 million euro. The majority of sales were attributable to hip-related products. Overall, the Group places great value on research and development processes: a total of 268 existing patents have already been approved, with a further 141 applications outstanding.
CEO Francesco Siccardi commented: “We believe now is the right time to offer shares to the public, seek a listing and broaden our shareholder base. We believe the planned IPO will allow us to further increase awareness and visibility of Medacta and facilitate access to international talent."
Medacta is headquartered in Castel San Pietro, Ticino, and operates offices in 12 countries overall. The company sells its products in 20 countries in total.